Analysis of efficacy and safety of mosapride combined with pancreatic kallikrein in the treatment of diabetic neurogenic bladder
10.3760/cma.j.issn.1008-6706.2013.18.026
- VernacularTitle:莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱的疗效及安全性分析
- Author:
Hongxing WANG
;
Chunling ZHAO
;
Dejun ZHAO
- Publication Type:Journal Article
- Keywords:
Mosapride;
Pancreatic kininogenase;
Diabetes mellitus;
Urinary bladder,neurogenic;
Treatment outcome;
Quality of life
- From:
Chinese Journal of Primary Medicine and Pharmacy
2013;20(18):2784-2786
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of mosapride combined withpancreatic kallikrein in the treatment of diabetic neurogenic bladder(DNB).Methods According to the digital table,120 patients with DNB were randomly divided into the control group and the observation group,each group 60 cases,All patients received basic treatment,including reducing blood glucose,reducing blood pressure,nutrition nerve and regulating blood lipids,and the observation group was accepted the treatment of original enzyme plus mosapride pancreatic kinin on basis of the above treatment.The treatment time of the two groups was both 3 weeks,The effect,blood sugar,blood hpids,urodynamic,quality of life,and the incidence of adverse reactions were observed.Results The total effective rate of the observation group was 93.33％,which was significantly higher than that of the control group (65.00％) (χ2 =14.602,P ＜ 0.01) ；the adverse reaction rate of the observation group was 8,33％,which was significantly lower than that of the control group(20.00％)(χ2 =11.368,P ＜ 0.01),Conclusion Mosapride combined with pancreatic kallikrein in thetreatment of DNB has better effect,and could significantly improve the clinical symptoms and quality of life of patients.So it should be promoted and applied.
